BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

By WebmasterJuly 29, 2019November 1st, 2024No Comments

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
REL-1017 is a novel NMDA receptor antagonist in development as a rapidly acting oral agent for the treatment of depression

See more here

Previous PostRenovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease
Next PostHHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRenovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease

Next PostHHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections